Amgen (AMGN) Raises 2026 Revenue and Profit Outlook Amid Strong Q3 Performance
Amgen (AMGN) Raises 2026 Revenue and Profit Outlook Amid Strong Q3 Performance GuruFocus
Covered in this story
Analyst targets on Amgen
- Oppenheimer: $439 → $480 by Oct 2027 · Outperform via Investing.com India
- Scotiabank: $432 → $500 by Oct 2027 · outperform via MarketBeat
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 8 Oct 2026.
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.